ARTICLE | Clinical News
Femara letrozole once daily oral aromatase inhibitor regulatory update
January 16, 2001 8:00 AM UTC
The FDA granted marketing approval for Femara as a first-line treatment for advanced breast cancer in post-menopausal women. The product is approved in the U.S. as second-line therapy following diseas...